World's First Messenger RNA Combination Vaccine Launched

The European Commission (EC) has officially approved mCombriax (mRNA-1083), Moderna's (MRNA) messenger RNA (mRNA) combination vaccine for the simultaneous prevention of COVID-19 and influenza, on April 20, 2026. This approval is based on the results of a Phase 3 clinical trial (NCT06097273) conducted on adults aged 50 and over, which demonstrated non-inferiority and superior immunogenicity compared to the simultaneous administration of existing individual vaccines. Specifically, it showed a strong neutralizing antibody response against influenza A (H1N1 and H3N2) and B (Victoria lineage) viruses, as well as the Omicron XBB.1.5 variant of COVID-19. This is considered a significant event that dramatically improves vaccine convenience and presents a new paradigm for preventing respiratory infectious diseases annually.

Competition for Platform Leadership Among Rival Bio Companies

The European approval of mCombriax has solidified Moderna's position as a leader in the messenger RNA platform. Currently, its main rival, the Pfizer (PFE) and BioNTech (BNTX) alliance, is developing an mRNA-based combination vaccine, and Novavax (NVAX) also has a pipeline utilizing protein recombinant technology, making the competition for market share very intense. In particular, there is the challenge of breaking through the defenses of traditional influenza vaccine giants such as Sanofi (SNY) and GlaxoSmithKline (GSK). Nevertheless, the mRNA platform's inherent ability to rapidly respond to variants and its production flexibility are likely to provide Moderna with a long-term competitive advantage.

Synergy of Capturing Multi-Billion Dollar Market and Alleviating Vaccine Fatigue

According to major market research firms, the market for COVID-19 and influenza combination vaccines in the G7 countries is projected to reach approximately $8 billion (approximately 10 trillion KRW) annually. For reference, the global influenza vaccine market alone is approaching $9 billion in 2025, so the growth potential of combination vaccines is enormous. In the medical field, it is expected that reducing the number of injections from two to one will lower vaccine fatigue and significantly increase vaccination rates. This convenience can reduce public health care costs and become a major driver of Moderna's core revenue and corporate value.

Overcoming Regulatory Barriers and Global Commercialization Challenges

With mCombriax receiving approval from the European Union, the first step has been taken, but there are still many challenges to be solved, such as barriers to entry into the US market and price negotiations. Previously, Moderna had to withdraw its application for approval from the US Food and Drug Administration (FDA) in 2025 after being asked for additional efficacy data, so it needs to resolve the uncertainty surrounding its future entry into the US. In addition, there are initial commercialization hurdles, such as passing the stringent cost-effectiveness evaluations of European national health authorities and obtaining reasonable reimbursement. Furthermore, minimizing the costs and logistical constraints of the strict cold chain maintenance required for mRNA vaccines will also be a key factor in the expansion of the global market.